Press Releases

Endonovo Announces First Commercial Sales for SofPulse Wearable Electroceutical for Post-Operative Pain and Edema

Download PDF

Seeking Distribution Partners in Europe for CE-Marked Electroceutical™ Device for Promotion of Wound Healing, Reduction of Pain and Post-Operative Edema

LOS ANGELES, CA, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive wearable Electroceutical™ devices, today announced the first commercial sales of SofPulse™, its non-invasive, wearable Electroceutical™ device. SofPulse™ is the Company's FDA-Cleared Electroceutical™ System for the palliative treatment of post-operative pain and edema in superficial soft tissues. Furthermore, the Company announced it is seeking distribution partners in Europe for SofPulse™, which is CE-Marked for the promotion of wound healing, reduction of pain and post-operative edema.   

"We are very excited to begin sales of SofPulse™ under Endonovo management," said Endonovo CEO, Alan Collier. "Our wearable Electroceutical™ was FDA-Cleared in 2008, but no significant effort to commercialize this revolutionary technology was ever undertaken. SofPulse™ has shown 80% acceleration in pain relief in breast augmentation patients and 2-fold less narcotics use in breast reconstruction patients."

"As we battle an opioid epidemic we must look for novel ways to relieve pain for people suffering from chronic pain, as well as preventing people undergoing surgical procedures from becoming dependent on narcotics. We believe our wearable Electroceutical™ can drastically reduce the need for pain medication use and improve the lives of millions of people suffering from pain."

"Unlike many of our competitors using electrical stimulation, some of whom have signed agreements with large device and pharmaceutical companies, our devices don't simply mask the pain, they address the underlying issue causing the pain, which is inflammation," stated Mr. Collier.  

"We are actively seeking to establish channel partnerships with global device and healthcare companies to commercialize our wearable Electroceuticals™ in Europe," concluded Mr. Collier.

About SofPulse™ Electroceutical™ System

SofPulse™ is an easy-to-place, non-invasive device that delivers targeted MicroCurrent Therapy (tMCT) to enhance post-surgical recovery, naturally. tMCT is an innovative process that uses proprietary technology to reduce pain and swelling. The therapy is non-invasive and non-pharmacologic, with no known side effects and no potential for overdose or dependency. SofPulse™ has been used effectively and studied extensively in soft tissue post-operative management. The low levels of microcurrent are completely safe and in fact, are 1000 times lower than those emitted by a mobile phone. SofPulse™ is manufactured, marketed and distributed through ADM Tronics Unlimited, Inc.

The Company's wearable Electroceuticals™ have been evaluated in 5 randomized, controlled clinical trials and have demonstrated significant reductions in pain, post-surgical edema and use of pain medication.    

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ addresses wound healing, pain, post-surgical edema and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ device using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ addresses chronic kidney disease, liver disease, cardiovascular and peripheral artery disease. The Company's non-invasive, wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact:

Endonovo Therapeutics, Inc.

Mr. Steven Barnes

Senior Vice President of Investor Relations

(800) 701-1223, Ext. 108

Source: Endonovo Therapeutics, Inc.

Investors: Sign Up for Email Alerts on Endonovo


Primary Logo

Source: Endonovo Therapeutics, Inc.